Pharmaceutical News

RSS

Shire announces findings from Phase 3 study data with Vyvanse

Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

13 Nov 2009

Idaho's U.S. Representatives oppose HR 3962: AARP disappointed

AARP is disappointed Idaho's U.S. Representatives chose to oppose the legislation, ignoring the worsening health care crisis in their home state.

13 Nov 2009

Health Canada approves ONGLYZA for type 2 diabetes treatment

Bristol-Myers Squibb Canada and AstraZeneca Canada today announced that Health Canada has approved ONGLYZA(TM) (saxagliptin) which improves all three key measures of glycemic control - hemoglobin A1c (A1c), fasting plasma glucose (FPG) and post-prandial glucose (PPG) - when taken in combination with other commonly used oral anti-diabetic agents (metformin or a sulfonylurea).

13 Nov 2009

Vanderbilt University researchers study role of statins in reducing flu-related deaths

Vanderbilt University Medical Center researchers are studying statins, the class of drugs long associated with lowering cholesterol, as a way to reduce H1N1-related deaths.

13 Nov 2009

CSL's H1N1 influenza vaccine receives approval from FDA for use in children ages 6 months and older

The U.S. Food and Drug Administration has approved the use of the CSL Limited's 2009 H1N1 influenza vaccine to include children ages 6 months and older. This vaccine was previously approved only for use in adults, ages 18 years and older.

13 Nov 2009

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

13 Nov 2009

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain.

13 Nov 2009

New and effective medicines underway for treating a wide range of diseases affecting women

Women's Health Weekly recently reported that America's pharmaceutical research and biotechnology companies are working on nearly 1,000 life-changing medicines for diseases affecting women, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines are awaiting approval by the U.S. Food and Drug Administration or are in human clinical trials.

13 Nov 2009

Intervention to reduce over-dispensing of asthma medications effective without compromising patient safety

Research presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting shows that an intervention to reduce over-dispensing and waste of asthma medications can succeed without compromising patient safety and can result in substantial cost savings.

13 Nov 2009

Ipsen receives marketing authorization in France for its 6-month sustained-release formulation of Decapeptyl

Ipsen, an innovation-driven global specialty pharmaceutical Group announces that the French regulatory authorities (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS) have today granted the marketing authorization to the 6-month sustained-release formulation of Decapeptyl® (triptorelin embonate 22.5 mg) for the treatment of locally advanced and metastatic prostate cancer.

13 Nov 2009

Bioniche Pharma acquires injectable drugs from Xanodyne Pharmaceuticals

Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Duraclon® (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP from Xanodyne Pharmaceuticals, Inc.

13 Nov 2009

CDC expected to revise estimated number of U.S. H1N1 deaths

Ahead of the anticipated CDC release of revised U.S. H1N1 (swine flu) death toll estimates, Reuters examines how the agency and WHO measure the impact of the virus, after both organizations "stopped trying to count actual cases months ago, once it became clear that H1N1 was a pandemic that would infect millions."

12 Nov 2009

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).

12 Nov 2009

Spectrum Pharmaceuticals reports consolidated revenues of $7.1M for the third quarter of 2009

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology, today reported financial results for the third quarter ended September 30, 2009.

12 Nov 2009

MAP Pharmaceuticals to sell up to $60 million of its registered common stock to Azimuth Opportunity

MAP Pharmaceuticals, Inc. today announced that it has secured a committed equity financing facility under which it may sell up to $60 million of its registered common stock to Azimuth Opportunity Ltd. MAP Pharmaceuticals is not obligated to utilize any of the $60 million facility, which has a term of 24 months.

12 Nov 2009

Review of Mersana Therapeutics's lead compound, XMT-1001 to be published

Mersana Therapeutics, a platform-based cancer therapeutics company, announced today that a review of the Company's lead compound, XMT-1001, will appear in the November 12, 2009 special issue of Advanced Drug Delivery Reviews on Polymer Therapeutics: Clinical Applications and Challenges for Development.

12 Nov 2009

Baby Boomers seek alternatives for prescription only treatments for menopause symptoms

As an increasing number of women from the Baby Boomer generation approach or have already reached menopause, more are seeking alternatives to prescription only treatments for menopause symptoms, and more are discovering Femnene and its line of feminine products designed specifically for a woman during and after the change of life.

12 Nov 2009

A discreet option for pain relief in the workplace

Employers say that back pain-related problems account for over 100 million lost workdays a year. In a cutthroat economy with unemployment at a record high, this is especially disconcerting news. Employees cannot afford to risk losing their jobs to other candidates while stuck home in bed recuperating. With 80% of Americans experiencing back pain in their lifetime, back issues have serious implications on job security and can negatively affect even the most dedicated employee’s performance abilities and job attendance.

12 Nov 2009

ORC Guideline's recent research on the impact of social media and pharmaceutical marketing

Chief Research Officer Morris S. Whitcup, Ph.D., of ORC Guideline (an infoGROUP company) (NASDAQ: IUSA) will present findings of the company’s recent research on the impact of social media on fair balance and pharmaceutical marketing at a Food and Drug Administration (FDA) public hearing later this week. The hearing will address the issue of fulfilling requirements for fair balance and risk disclosure in internet and social media promotions. The ORC Guideline study examined consumer habits in researching information about pharmaceutical products online.

12 Nov 2009

Stelara expected to change dermatologists’ prescribing habits and alter patient flow models

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Centocor Ortho Biotech's Stelara, the first interleukin (IL)-12/23 inhibitor to enter the psoriasis drug market in the U.S., is expected to change the prescribing habits of dermatologists and substantially alter patient flow to currently marketed biologic agents, including Amgen's Enbrel and Abbott's Humira.

12 Nov 2009

Pharmaceutical News

Shire announces findings from Phase 3 study data with Vyvanse

Idaho's U.S. Representatives oppose HR 3962: AARP disappointed

Health Canada approves ONGLYZA for type 2 diabetes treatment

Vanderbilt University researchers study role of statins in reducing flu-related deaths

CSL's H1N1 influenza vaccine receives approval from FDA for use in children ages 6 months and older

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

New and effective medicines underway for treating a wide range of diseases affecting women

Intervention to reduce over-dispensing of asthma medications effective without compromising patient safety

Ipsen receives marketing authorization in France for its 6-month sustained-release formulation of Decapeptyl

Bioniche Pharma acquires injectable drugs from Xanodyne Pharmaceuticals

CDC expected to revise estimated number of U.S. H1N1 deaths

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Spectrum Pharmaceuticals reports consolidated revenues of $7.1M for the third quarter of 2009

MAP Pharmaceuticals to sell up to $60 million of its registered common stock to Azimuth Opportunity

Review of Mersana Therapeutics's lead compound, XMT-1001 to be published

Baby Boomers seek alternatives for prescription only treatments for menopause symptoms

A discreet option for pain relief in the workplace

ORC Guideline's recent research on the impact of social media and pharmaceutical marketing

Stelara expected to change dermatologists’ prescribing habits and alter patient flow models

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News